The clinical benefit of proteasome inhibitors in multiple myeloma was originally proposed to be a consequence of the genetic aberrations that activate NF-κB signaling in multiple myeloma cells, for example as mentioned above [151, 152], that impose NF-κB-dependence [160]. Here, NFKB1 is linked to plasma cell myeloma.